



14 December 2016

AIM: RENE

**ReNeuron Group plc**  
("ReNeuron" or the "Company")

**Director Share Purchase**

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 14 December 2016 that, on the same day, Olav Hellebø, the Company's Chief Executive Officer, acquired 346,644 ordinary shares of 1p each ("Ordinary Shares") at a price of 2.8848p per share.

Following this share purchase, Olav Hellebø's total beneficial interest in the Company is 669,422 Ordinary Shares, representing 0.021 per cent of the Company's total voting rights.

**ENQUIRIES:**

**ReNeuron** +44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer

Michael Hunt, Chief Financial Officer

**Buchanan** +44 (0) 20 7466 5000

Mark Court, Sophie Cowles, Stephanie Watson

**Stifel Nicolaus Europe Limited** +44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)

**About ReNeuron**

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic

candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at [www.reneuron.com](http://www.reneuron.com).

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

**(Disclosure in relation to purchase of Ordinary Shares)**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Olav Hellebø	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Chief Executive Officer	
b)	Initial notification /Amendment	Initial notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	ReNeuron Group plc	
b)	LEI	N/A	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 0.01p  RENE – GB00B0DZML60	
b)	Nature of the transaction	Purchase of ordinary shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		2.8848p	346,644
d)	Aggregated information	N/A	
e)	Date of the transaction	14 December 2016	
f)	Place of the transaction	London Stock Exchange, AIM Market	